Browsing Tag
Telix Pharmaceuticals
7 posts
CSL (ASX: CSL) crashes 17.7% to A$98.59 after FY26 guidance cut and $5bn impairments
CSL cut FY26 NPATA to US$3.1 billion and flagged US$5 billion in impairments. The third downgrade in ten months is repricing the entire ASX healthcare sector.
Telix Pharmaceuticals (ASX: TLX) orders four IBA cyclotrons to build in-house isotope production at RLS radiopharmacy network
Telix (ASX: TLX) orders four IBA Cyclone KIUBE cyclotrons for U.S. RLS radiopharmacy sites. What it means for isotope supply chains. Read more.
ASX healthcare sector falls harder than the broader market as rate shock and Middle East war pressure high-multiple stocks
ASX healthcare stocks fell 2.47% on 19 March, lagging every other defensive sector. Here's what's driving CSL, Pro Medicus and Cochlear lower. Read more.
Breakthrough in kidney cancer imaging: FDA fast-tracks Telix Pharmaceuticals’ TLX250-CDx
The United States Food and Drug Administration (FDA) has accepted the Biologics License Application (BLA) for Telix Pharmaceuticals…
Telix Pharmaceuticals to acquire ImaginAb assets to advance radiopharmaceutical development
Telix Pharmaceuticals Limited, a global leader in therapeutic and diagnostic radiopharmaceuticals, has announced a strategic acquisition of assets…
Telix Pharmaceuticals submits NDA for Pixclara to advance brain cancer imaging
Telix Pharmaceuticals Limited (ASX: TLX) has taken a significant step in the realm of neuro-oncology by submitting a…
Telix Pharmaceuticals advances prostate cancer treatment with successful TLX592 study
Telix Pharmaceuticals Limited (ASX: TLX) has announced the successful completion of the CUPID Phase I dose escalation study…